Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LYLP - according to recently filed/mailed out information, they expect the American Express deal to be signed by August 11, 2004. Alot is riding on this deal with AMEX. I expect the stock to be in play this next week leading up to that date and also we should expect press on the subject.
not being a pumper....but PGLAF gonna run again.
http://finance.yahoo.com/q/cq?d=v1&s=PGL.AX%2c+PGLO.AX%2c+PGLAF
see the PGL.AX & PGLO.AX the night before (tonight) down under.
PGLAF gonna run again Tuesday...
PGLAF gonna run again this week:
http://finance.yahoo.com/q/cq?s=PGL.AX%2c+PGLO.AX%2c+PGLAF&d=v1
Hope everyone is still holding strong.
PGLAF should be $2.97 USD based on the conversion price of last nights close of PGL @ $3.86 AUD. Arbitrage anyone?
We'll have to see how today plays out and tonights action down under.
http://finance.yahoo.com/q?d=t&s=PGL.AX
PGL up big down under on monster volume and no news.
PGLAF should be in play today...be careful.
PGLAF - observations
Seems the date of May 2005 is fairly critical.
That is the option expiry for the PGLO option w/ strike price of 2.50AUD. That is also around the timeframe from which Medigen will IPO (Progen is an investor), Clinical data will be finished for PI-88/PI-166, among other things. This one has about a year I would say...put it on your radar and slowly accumulate.
PGLAF - Phase 2 liver trial started, finally.
PI-88 Phase II Clinical Trial Targeting Liver Cancer Launched
July 13, 2004 22:36:00 (ET)
BRISBANE, Australia, Jul 13, 2004 /PRNewswire-FirstCall via COMTEX/ -- Progen Industries Limited (PGLAF, Trade), an oncology-focused drug discovery and development company, announced the commencement of the fourth and largest in the series of PI-88 Phase II clinical trials. This trial will evaluate PI-88, the company's lead anti-cancer compound, in patients with primary liver cancer (hepatocellular carcinoma or "HCC") following surgical removal (resection) of the primary tumor.
The launch of the Phase II HCC trial is very significant to PI-88's clinical development as it represents the first time that PI-88 is being evaluated for its ability to prevent/reduce recurrence of disease. Following resection of the primary liver tumor, patients present with a low tumor burden providing the opportunity to demonstrate PI-88's anti-angiogenic and anti-metastatic mechanism of action. Although early diagnosis and treatment may improve patient well-being and survival, HCC recurs frequently in the first 12 months after hepatic resection. This trial will examine the effect of PI-88 given as an adjuvant therapy following curative hepatic resection.
Asian clinical trial collaborator Medigen Biotechnology Corporation is conducting the trial in Taiwan under Progen regulatory (FDA) sponsorship. The large randomized study will involve approximately 340 patients with two treatment arms (each arm representing one different dose level of PI-88) and a control arm (no treatment). The objective of the trial will be to determine the number of patients with recurrence over 48 weeks post surgery with or without PI-88 as adjuvant therapy. This announcement coincides with the treatment of the first patient in the trial. The participating hospitals namely, National Taiwan University Hospital (Taipei), Chang Gung Memorial Hospital (Linkou), Veterans General Hospital (Taichung) and China Medical University Hospital represent a broad cross section of the most prestigious hospitals in Taiwan.
"We are looking forward to seeing the results of this trial," commented Progen's Managing Director Lewis Lee. "To determine a drug's ability to prevent recurrence via inhibiting angiogenesis generally requires a huge investment with a trial program that can last many years. This is impractical and undesirable in terms of research dollars needed, as well as having impact on the therapy's patent life. However, the current trial design and target disease represents a very sensible and practical opportunity to assess PI-88's potential to improve cancer patient survival after tumor bulk has been removed. By attacking the growth of blood vessels to the tumor (angiogenesis) and the spread of the tumor (metastasis) we hope PI-88 will reduce the number of patients that have disease recurrence in the 12 months following surgery."
This trial represents the fourth in a series of PI-88 Phase II trials launched. In previous trials, PI-88 has demonstrated benefit and disease impact in some patients. From the PI-88 Phase I single agent trial completed in January this year, over 40% of the melanoma patients showed retarded tumor growth for periods lasting up to 35 months. The Phase II multiple myeloma trial completed in August 2003 showed 41% of patients with cancer stabilization for periods up to 2 years. These data has provided the company with the additional confidence to expand the current PI-88 Phase II clinical program which now includes clinical investigation into Melanoma, Multiple Myeloma, Non-Small-Cell Lung Cancer and now HCC.
SOURCE Progen Industries Limited
LYLP - LoyaltyDisappoint.
Steve & others, what is your near term outlook for this one.
Conference call yesterday mentioned American Express Rewards as a client that will go into effect next month...? I think. That was only positive takeaway that I got. Otherwise, this one seems like dead money. I hope I'm wrong.
LYLP: PR tomorrow to announce next week's meetings, etc.
LYLP roadshow begins next week.
This just in from ROI Group.
it's a long one...but glad they met the schedule.
what is your feeling after a first glance?
:) rc
FYI, Craig @ the company said they were announcing an acquisition on Monday. Said he expected the shares would be post split about .25 cents at least. Isn't that illegal to give out that kind of info? Course, I'm not complaining. I cannot even sell the shares until Monday anyways...due to settlement date. But, .25+ would be awesome return for a couple days.
LYLPE NEWS!!
-----Original Message-----
From: Mickey Freeman [mailto:mfreeman@schoolpop.com]
Sent: Thursday, June 17, 2004 10:59 AM
To: 'rcaselli'
Subject: RE: LYLPE
We're reviewing the EDGAR proof right now.
did anybody take advantage of FHFP??
seems caught in the transition to EXTP.
i took a nibble...and a gamble.
curious if anybody has any information to share on the subject.
:) Rick
Sitting on a nice position of LYLP. Financials to be out soon, right DC?
I like what I read in the marketing kit...if you don't have it yet, order it from ROI folks.
What are your guys' target prices for the exit?
Interesting the option strike prices up to $5+ for that one senior executive.
Wonder if it could ever go that high?....lolol.
:) Rick
BPNT/LYLP:
tt guys over @ ROI NY. very favorable discussion. they overnighted me an investor kit. liked what i read. this company has good things in store for the future. share price appreciation will be realized soon.
stay tuned.
U.S. FDA Grants Orphan Drug Status to PI-88 for Melanoma!!
PGLAF TO THE MOON!!
http://biz.yahoo.com/prnews/040503/lnm014_1.html
tt mickey freeman @ BPNT.
key dates approaching.
4/15, 5/5, 5/17.
8k, 10Q?, ???.
have info at my office...but couldn't post there.
maybe volume in anticipation of these dates?
big day for PGLAF guys....
be careful if you are trading ST.
talked w/ BPNT CEO yesterday...said that the everything will become quite clear in the next couple months. they have filings in april & may. good enuf for me. i'm a holder.
:) rick
i got the .429 shares but no cash....what's the dealio?
anybody else seeing similar things...and care to share their perspective??
:) rick
ssp, yes, and i'm still holding..for much higher.
speculation is that the recent approval of genetech's avastin means big stuff in store for progen...maybe a partnership? buy out? either way, we're going much higher IMO.
what would cause the bid/ask to do what it's doing now?
:) rick
PGLAF - ON FIRE TODAY!
Can someone please educate me regarding why the bid is $2.21 and the ask is 2.08 in real-time? What would make this happen...very strange.
:) Still very happy with the current share price...anyone in this, too??
RC
PGLAF - BIG MOVER TODAY!!
Half Year Report - Progen on Track to Meet Milestones
February 27, 2004 06:02:58 (ET)
BRISBANE, Australia, Feb 27, 2004 /PRNewswire-FirstCall via Comtex/ -- Progen Industries Limited (PGLAF, Trade), a progressive Australian drug development company, today announced its half year financial results to December 31st, 2003 and said the company is on track to meet its objectives for 2004.
Progen's operating loss for the half-year ending 31 December 2003 was $1,895,201. "This is a good result when compared to the loss of $4,213,824 in 2002," Progen's Chief Financial Officer, Milton McColl commented. "This was largely attributable to the profit, $929,999 made from the divesture of the Life Sciences business unit, a transaction that enabled Progen to sharpen its cancer drug development focus. In addition, the result was due to Medigen Biotechnology Corporation's profit of $183,910 when equity accounted. This was caused by the increase in Medigen's revenues and an increase in the share price of their investment."
The following schedule summarises the results for the half-year ending 31 December 2003.
2003 2002
$'000 $'000
Revenue from commercial services sales 2,470 2,326
Revenue from other operating activities 705 705
Revenue from sale of discontinued operation 1,175 --
Total Revenue 4,350 3,031
Operating profit (loss)
before research and development (76) (503)
Research and development expenditure (2,003) (2,824)
Operating profit (loss)
after research and development (2,079) (3,327)
Share of equity profit (loss)
in associate entity 184 (887)
Operating loss (1,895) (4,214)
Net Tangible Assets 17,767 14,399
Net Assets per share (cents) 52.0 59.0
Cash on hand 14,974 8,348
Today also marks an important milestone in Progen's field of research. Genentech, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Avastin(TM) (bevacizumab), a Vascular Endothelial Growth Factor (VEGF) inhibitor, to be used in combination with chemotherapy as a treatment for patients with metastatic cancer of the colon or rectum. Stephen Chang, Progen's Chairman commented, "This is outstanding progress for the anti-angiogenesis research area and helps build our confidence in our Phase II compound, PI-88. PI-88 is small-molecule-based and rather than relying on a single mode of action to induce an anticancer response, it inhibits blood vessel growth, or angiogenesis via multiple growth factors including Fibroblast Growth Factors (FGFs) and VEGF, as well as inhibiting other angiogenic agents, including heparanase."
Bolstered by this positive announcement in the angiogenesis research area, the main focus for the company in the calendar year 2004 will be to continue to develop a robust clinical dataset for the lead anti-cancer compound PI-88 and continue the ongoing partnering initiative. Stephen Chang, commented, "In the past six months PI-88 has certainly moved forward its clinical development. Signs of efficacy and a good safety profile have emerged from the clinical program with some patients continuing to receive PI-88 for periods lasting up to 30 months. Two new Phase II trials have commenced just recently for patients with advanced melanoma and non-small cell lung cancer, respectively, and our centers are actively recruiting patients across Australia and the US. We are very excited by the next 12 months and beyond."
SOURCE Progen Industries
Sarah Meibusch of Progen Industries, +61-7-3273-9100, or
Sarah.Meibusch@progen.com.au
http://www.prnewswire.com
Copyright (C) 2004 PR Newswire. All rights reserved.
PGLAF - BIG MOVER TODAY.
Rumor of big news down under...we shall see.
thanks SSP. so that i am clear, if he buys today...he is entitled, correct?
BPNT - QUICK QUESTION FOR THE EXPERTS...
If someone bought this stock today, would they get the divvie and fractional shares? Buddy is very interested in buying if so, and the CFO at the company wouldn't say one way or the other. Settlement date vs. Purchase date....I guess. Tried to dig through the posts to verify and couldn't.
Thanks in advance if this has already been answered.
:) Rick
OYMP - .40 x .45
I would appreciate some help here. I have this stock from .30 and curious if it is dead now that the previous news has been already been released and digested by the market. Anyone still holding this POS? What are thoughts. Appreciate your insights.
QMCE - News after the bell...
http://biz.yahoo.com/bw/040122/225950_1.html
Might move tomorrow. Whatcha think?
Nice Progen Newz this a.m. - PGLAF
http://biz.yahoo.com/prnews/040120/lntu020_1.html
Not to post about just <one> stock...but this is a spring that has been tightening and tightening for some time. Will probably be huge in a year if you have some patience. Very bullish about the long-term prospects here.
:) Rick
More PGLAF......the pressure cooker continues to build.
Progen Granted Anti-Angiogenesis Antibody Patent
Press Release Source: Progen Industries
Tuesday October 28, 8:42 pm ET
BRISBANE, Oct. 28 /PRNewswire-FirstCall/ -- Progen Industries Limited (Nasdaq: PGLAF - News; ASX: PGL - News) announced today that it has recently broadened its intellectual property position with the receipt of E.U. Patent No. 0669988. The patent entitled "Angiogenesis Inhibitory Antibodies" broadly covers antibody approaches to the inhibition of angiogenesis by directly inhibiting endothelial cell growth.
Angiogenesis is a critical step in cancer and is the process by which new blood vessels are formed to establish and grow tumors. Inhibiting angiogenesis can inhibit tumor growth and prolong life for cancer patients. This has recently been confirmed by Genentech's (Nasdaq: DNA - News) antibody, Avastin® that has demonstrated a survival benefit in patients with metastatic colorectal cancer and is the subject of their recent Biologics License Application (BLA) filing with the U.S. Food and Drug Administration (FDA) for its eventual release to the market.
Progen's new patent grant broadens the company's intellectual property coverage in one of the most heavily researched areas - angiogenesis and specifically the area of inhibiting endothelial cell growth. Endothelial cells form the walls of blood vessels and their growth or proliferation, is a key step in the process of providing blood supply to growing tumors. Progen claim in their patent a novel antibody-related approach to preventing endothelial cells forming these new blood vessels to feed tumors thereby inhibiting angiogenesis.
Robert Don PhD, Progen's Vice President for Research and Development commented, "Interest in therapeutic anti-angiogenic antibodies for the development of drugs has grown and was recently validated, so our patent covers a space in what is becoming an important area for drug development. Our lead drug PI-88 emerged from our related angiogenesis research program and Progen's drug discovery team continues to work on expanding our drug portfolio. This most recent patent grant completes coverage gained by patents issued in the United States (US5677181 & US5874081) and Australia (AU673865). It will complement our 6 patent families in the antiangiogenesis field with 26 granted patents and 17 patent applications."
Progen's lead small-molecule drug candidate, PI-88 also targets angiogenesis, in this case via the inhibition of several growth factors necessary for blood vessel growth, such as VEGF, FGF-1 and FGF-2, along with the enzyme heparanase. PI-88 is showing promise in a Phase I solid tumor trial as a single-agent, where one third of cancer patients treated to date have experienced stable disease over periods up to 27 months. All patients in this study have advanced or terminal stage disease where life expectancy is short and where all other effective therapy options are either not available or have failed.
------------------------------------------------------------------------
Source: Progen Industries
Press Release Source: Progen Industries Limited
Bonus Options Offered to Progen Shareholders
Tuesday October 21, 11:24 pm ET
BRISBANE, Australia, Oct. 21 /PRNewswire-FirstCall/ -- Progen Industries Limited (ASX: PGL, Nasdaq: PGLAF) today announced that the Board of Directors has resolved to offer a bonus option issue to all shareholders at no cost. The issue will be prescribed on the basis of one option for every eight shares held on the record date. The record date will be advised following the AGM scheduled for October 31st 2003.
The bonus options will be tradeable and the exercise price will be $2.50 per new share, i.e. at the same price and exercise conditions for which employees and directors non-tradeable options are being proposed for shareholder approval at the AGM. The options expire on May 31st 2005. The Company will apply to the ASX for the listing of the options. A prospectus will be mailed to shareholders eligible to participate in the bonus option issue once the record date has been set.
Progen's Chairman Stephen Chang said: "The primary purpose of the proposed bonus issue is to support Progen's growth strategy. We are very encouraged by the clinical data emerging from PI-88's clinical trial program to date and are aggressively seeking an out-licensing deal with a Big Pharma or Biotech company that will take the product through late-stage clinical development, registration approval and eventual release to the market. Simultaneously, the company plans to expand its drug development pipeline through development of our in-house drug discovery platform and in-licensing opportunities. These activities are intended to drive further value creation for the Company and secure Progen's future as a competitive and progressive biotechnology company."
The Company was in the process of finalizing the details of the Prospectus, which will outline the terms and conditions of the bonus options including the record date.
------------------------------------------------------------------------
Source: Progen Industries Limited
Ex-Dividend FIASCO.
Hey, given all the hoopla re: MSSI and the divies...I thought I would offer up a FIASCO that I recently experienced.
A few months ago, I bought a stock called CKCM - Click Commerce.
They had declared a $2.50 one-time dividend...and at the time, the stock was at $4.00. A buddy and I took the plunge and bought the stock. The day that the dividend showed up in my account, in cash, I called ETRADE and asked "Is the money really there?" To which they replied yes. The stock was still trading at $4.00ish. Then I sold the stock and had the dividend. A week or so later, they took the dividend cash out of my account. When I phoned HR and also ETRADE, everyone played stupid. Apparently, "The Market" took the money back. I screamed out and blamed ETRADE as they said the money was there and I could sell. They ended up crediting me "some" money to make things good...since I bitched hard. But, I would caution all that things may still net out differently than you think...once things settle.
Just beware.
Bottomline, if it sounds too good to be true, it probably is.
~Rick
BULL,
it is 90 days above $5 bucks unless they give 'em an exception of some sort.
~Rick
Mt. Blanc....
You still bullish on PGLAF?
I'm still holding....and used last week's dip to buy more.
Let me know your thoughts....
Thanks,
~Rick
PGLAF - Check out the volume recently....
Something BIG is up. If the grant from the Australian's comes through.....the top is going to blow off.
First mentioned here by Mt. Blanc sub $1.00....with minimal volume.
I have loaded the truck from .80's on up to 1.25....and I'm holding for $10.
LSTA - Nice move up to a penny. (anyone else in this POS?)
PGLAF - Nice base here...no? (anyone else holding this one?)
Mentions here:
PGLAF - HOLDING NICE LEVEL HERE AT .80ish.
CHWE - WOWOW. This one has climbed a ton since first mention.
LSTA - Was RRUN and up big today on big volume. Volume has been building last few days.
Are others in on these....?
What are targets....?
HUH?? Please elaborate for those less fortunate in understanding this.
RRUN symbol changes to LSTA effective 07/11/2003.